131 related articles for article (PubMed ID: 15678759)
1. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection.
Gono T; Matsuda M; Shimojima Y; Ishii W; Koyama J; Sakashita K; Koike K; Hoshii Y; Ikeda S
Amyloid; 2004 Dec; 11(4):245-56. PubMed ID: 15678759
[TBL] [Abstract][Full Text] [Related]
2. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
3. [Three patients with primary AL amyloidosis treated by high-dose melphalan with autologous peripheral blood stem cell transplantation].
Mukai S; Kanashima H; Ogawa Y; Nakao T; Teshima H; Yamane T
Gan To Kagaku Ryoho; 2012 Apr; 39(4):625-7. PubMed ID: 22504689
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients.
Tazawa K; Matsuda M; Yoshida T; Gono T; Katoh N; Shimojima Y; Ishii W; Fushimi T; Koyama J; Ikeda S
Intern Med; 2008; 47(17):1517-22. PubMed ID: 18758127
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of primary AL amyloidosis by VAD therapy, high-dose melphalan, and autologous peripheral stem cell transplantation.
Yamazaki O; Ubara Y; Suwabe T; Nakanishi S; Hoshino J; Sawa N; Hayami N; Yamanouchi M; Takemoto F; Kenmei T; Masuoka K; Oohashi K
Clin Exp Nephrol; 2009 Oct; 13(5):522-525. PubMed ID: 19499180
[TBL] [Abstract][Full Text] [Related]
7. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation.
Gono T; Matsuda M; Dohi N; Hoshi K; Tada T; Sakashita K; Koike K; Aizawa M; Ikeda S
Intern Med; 2003 Jan; 42(1):72-7. PubMed ID: 12583623
[TBL] [Abstract][Full Text] [Related]
8. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Hazenberg BP; Croockewit A; van der Holt B; Zweegman S; Bos GM; Delforge M; Raymakers RA; Sonneveld P; Vellenga E; Wijermans PW; von dem Borne PA; van Oers MH; de Weerdt O; Spoelstra FM; Lokhorst HM;
Haematologica; 2015 May; 100(5):677-82. PubMed ID: 25661441
[TBL] [Abstract][Full Text] [Related]
9. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
[TBL] [Abstract][Full Text] [Related]
10. Nephrotic syndrome due to primary systemic AL amyloidosis, successfully treated with VAD (vincristine, doxorubicin and dexamethasone) alone.
Matsuda M; Gono T; Katoh N; Yoshida T; Tazawa K; Shimojima Y; Ishii W; Fushimi T; Ikeda S
Intern Med; 2008; 47(6):543-9. PubMed ID: 18344643
[TBL] [Abstract][Full Text] [Related]
11. How to treat patients with systemic amyloid light chain amyloidosis? Comparison of high-dose melphalan, low-dose chemotherapy and no chemotherapy in patients with or without cardiac amyloidosis.
Hoshino J; Ubara Y; Sawa N; Sumida K; Hiramatsu R; Hasegawa E; Suwabe T; Hayami N; Yamanouchi M; Takemoto F; Taniguchi S; Takaichi K
Clin Exp Nephrol; 2011 Aug; 15(4):486-92. PubMed ID: 21387097
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of intensive chemotherapy in AL amyloidosis: usefulness of flow cytometric analysis of plasma cells in bone marrow.
Matsuda M; Gono T; Shimojima Y; Sakashita K; Koike K; Ikeda S
Amyloid; 2003 Dec; 10(4):250-6. PubMed ID: 14986484
[TBL] [Abstract][Full Text] [Related]
13. High-dose melphalan followed by autologous stem cell support in primary systemic AL amyloidosis with multiple organ involvement.
Shimojima Y; Matsuda M; Ishii W; Koyama J; Yamamoto K; Shimodaira S; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):484-9. PubMed ID: 15942100
[TBL] [Abstract][Full Text] [Related]
14. A case of secondary plasma cell leukemia resistant to novel agents, in which stringent complete remission was achieved and maintained for a long period of time after VAD therapy and tandem autologous transplantation.
Sekiguchi Y; Shimada A; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2014; 7(9):6313-22. PubMed ID: 25337285
[TBL] [Abstract][Full Text] [Related]
15. [A case of systemic amyloidosis treated by chemotherapy with autologous peripheral blood stem cell transplantation].
Mito A; Daga H; Ohashi N; Akita S; Shiomi K; Arita K; Fujiwara M; Asaoku H
Nihon Kokyuki Gakkai Zasshi; 2006 Aug; 44(8):583-8. PubMed ID: 16972617
[TBL] [Abstract][Full Text] [Related]
16. Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia.
Vela-Ojeda J; García-Ruiz Esparza MA; Rosas-Cabral A; Padilla-González Y; García-Chávez J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; García-León LD; Montiel-Cervantes L; Rubio-Borja ME
Ann Hematol; 2002 Jul; 81(7):362-7. PubMed ID: 12185504
[TBL] [Abstract][Full Text] [Related]
17. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
Mellqvist UH; Lenhoff S; Johnsen HE; Hjorth M; Holmberg E; Juliusson G; Tangen JM; Westin J;
Cancer; 2008 Jan; 112(1):129-35. PubMed ID: 17973267
[TBL] [Abstract][Full Text] [Related]
19. Vincristine, Doxorubicin, and Dexamethasone Induction before Autologous Stem Cell Transplantation in Patients with AL Amyloidosis: A Retrospective Comparison with Frontline Stem Cell Transplantation.
Iijima T; Sawa N; Nakayama Y; Oba Y; Ikuma D; Mizuno H; Yamanouchi M; Suwabe T; Wake A; Kono K; Hoshino J; Ubara Y; Ohashi K
Intern Med; 2022 Oct; 61(19):2853-2860. PubMed ID: 35228429
[TBL] [Abstract][Full Text] [Related]
20. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
Adam Z; Matýková M; Krejcí M; Pour L; Kissová J; Slechtová M; Chlupová G; Stavarová Y; Simonides J; Penka M; Mayer J; Hájek R
Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]